Peanut Allergy Treatment Market Size, Share, Growth and Forecast (2026 - 2036)

Peanut Allergy Treatment Market Analysis and Forecast by Fact.MR

• The global peanut allergy treatment market is estimated at USD 0.6 billion in 2025 and is forecast to expand at a CAGR of 11.6% to reach USD 2.01 billion by 2036.
• The market covers pharmaceutical and immunotherapy-based interventions for peanut allergy management, including epinephrine auto-injectors, antihistamines, and oral, epicutaneous, and sublingual immunotherapy products.
• Growth is shaped by rising peanut allergy prevalence in developed markets, expanding regulatory pathways for desensitization therapies, and growing clinical evidence supporting early intervention approaches in pediatric populations.

Summary of Peanut Allergy Treatment Market

• Market Snapshot
  • In 2025, the global Peanut Allergy Treatment Market was valued at approximately USD 0.6 billion.
  • The market is estimated to reach USD 0.67 billion in 2026 and is projected to attain USD 2.01 billion by 2036.
  • The peanut allergy treatment market is likely to expand at a CAGR of 11.6% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 1.34 billion between 2026 and 2036.
  • Epinephrine accounts for 47% of drug class share in 2026.
  • USA (12.5%) and China (12.0%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Rising prevalence of peanut allergy, particularly in pediatric populations across developed markets, is expanding the treatable patient base.
  • Regulatory approval of oral immunotherapy products for peanut desensitization is creating new treatment categories beyond emergency epinephrine use.
  • Growing clinical evidence supporting early intervention in young children is shifting treatment paradigms toward proactive allergy management.
  • Expansion of allergy specialist networks and hospital-based immunotherapy programs is improving patient access to desensitization protocols.
  • Increasing health insurance coverage for immunotherapy treatments is reducing out-of-pocket costs and supporting treatment adherence.
• Product and Segment View
  • Epinephrine accounts for 47% of the drug class segment in 2026, supported by strong adoption and proven market demand.
  • Hospital Pharmacy represents 56% of the distribution channel segment in 2026, with demand shaped by core use-case prevalence.
  • Allergy Desensitization accounts for 54% of the application segment in 2026.
• Key segmentation includes:
  • By Drug Class: Epinephrine, Antihistamines, Immunotherapies, Others
  • By Route of Administration: Injectable, Oral, Others
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others
  • By Application: Allergy Desensitization, Emergency Allergy Management, Preventive Care
• Geography and Competitive Outlook
  • North America is a leading regional market supported by established institutional infrastructure, regulatory frameworks, and strong adoption of advanced products.
  • Europe maintains steady demand shaped by regulatory standards, quality-focused procurement, and mature distribution channels.
  • Asia Pacific is the fastest-growing region, with USA and China leading through rising demand, expanding infrastructure, and growing awareness.
  • USA (12.5%) and China (12.0%) are the fastest-growing country markets during the forecast period.
  • Key companies include Aimmune Therapeutics, Inc., DBV Technologies S.A., Sanofi S.A., ALK-Abello A/S, Prota Therapeutics Pty Ltd, and others.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The peanut allergy treatment market is undergoing a structural shift from reactive emergency management toward proactive desensitization therapy. Oral immunotherapy is moving from clinical trial settings into real-world prescribing, creating a new revenue layer beyond traditional epinephrine auto-injectors. The competitive landscape is being reshaped by companies investing in epicutaneous and sublingual delivery formats that offer improved compliance, particularly in pediatric patients. Reimbursement coverage for immunotherapy remains the critical enabler of volume growth, and companies that secure payor support across major markets will capture disproportionate share in the coming decade.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Rising prevalence of peanut allergy, particularly in pediatric populations across developed markets, is expanding the treatable patient base.
• Regulatory approval of oral immunotherapy products for peanut desensitization is creating new treatment categories beyond emergency epinephrine use.
• Growing clinical evidence supporting early intervention in young children is shifting treatment paradigms toward proactive allergy management.

Key Market Constraints

• Lengthy and complex immunotherapy protocols create adherence challenges, particularly in pediatric patients requiring long-term dose escalation.
• Reimbursement uncertainty for newer immunotherapy formats in some markets constrains commercial uptake and physician adoption.
• Risk of severe allergic reactions during desensitization treatment limits adoption to supervised clinical settings and raises safety concerns.

Key Opportunity Areas

• Development of epicutaneous and sublingual immunotherapy delivery formats offers improved compliance and patient experience, particularly for younger children.
• Expansion of biologic therapies targeting underlying immune mechanisms creates potential for combination treatment approaches with improved efficacy.
• Growing peanut allergy prevalence in emerging markets across Asia Pacific creates new patient populations and demand for treatment infrastructure.

Segment-wise Analysis of the Peanut Allergy Treatment Market

• Epinephrine holds 47% of the drug class segment in 2026, supported by strong adoption and established demand patterns.
• Hospital Pharmacy represents 56% of the distribution channel segment in 2026, with demand shaped by core market drivers.
• Injectable holds 62% of the route of administration segment, with share expected to remain stable as the market evolves.

The peanut allergy treatment market is segmented by drug class, route of administration, distribution channel, application, and region. Epinephrine leads the drug class segment by value, while injectable leads the route of administration segment. Growth across segments is shaped by evolving demand patterns, new product development, and distribution channel expansion.

Which Drug Class Segment Dominates the Peanut Allergy Treatment Market?

Epinephrine is expected to account for 47% of the drug class segment in 2026. This leadership reflects the established role of epinephrine auto-injectors as the standard of care for emergency anaphylaxis management. Auto-injector and pre-filled syringe formats remain essential for patients at risk of severe allergic reactions, creating consistent replacement demand.

Immunotherapies are growing faster in percentage terms as oral, epicutaneous, and sublingual desensitization therapies gain regulatory approval and clinical adoption. Antihistamines continue to serve a supporting role in mild to moderate symptom management. The drug class mix is expected to shift gradually toward immunotherapy products as treatment paradigms evolve from emergency response toward proactive desensitization.

Which Route of Administration Dominates the Peanut Allergy Treatment Market?

Injectable products are expected to hold 62% of the route of administration segment in 2026. This dominance is anchored by epinephrine auto-injectors administered via intramuscular injection, which remain the primary emergency treatment for peanut-induced anaphylaxis. Subcutaneous delivery is also used in certain immunotherapy protocols.

Oral administration is the fastest-growing route, supported by the approval and commercialization of oral immunotherapy products. Oral tablets and liquid formulations for desensitization therapy are gaining traction as clinical protocols mature and reimbursement pathways expand. Other routes including topical and transdermal delivery are in earlier stages of development.

Which Application Segment Dominates the Peanut Allergy Treatment Market?

Allergy desensitization is expected to account for 54% of the application segment in 2026. Growth in this segment reflects the transition from emergency-only management toward long-term therapy designed to reduce allergen sensitivity over time. Long-term and dose escalation therapy protocols represent the primary sub-applications.

Emergency allergy management remains a significant application, accounting for the management of acute anaphylactic reactions through epinephrine administration. Preventive care, including early intervention and pediatric prevention programs, is an emerging application supported by clinical evidence favouring early-age desensitization.

Which Product Trend is Shaping the Next Phase of Growth in the Peanut Allergy Treatment Market?

Immunotherapy products, particularly oral immunotherapy, are emerging as the most significant growth driver in the peanut allergy treatment market. These products are transitioning from clinical trial settings into routine clinical practice, supported by regulatory approvals, expanding clinical evidence, and growing physician willingness to prescribe proactive desensitization rather than relying exclusively on emergency epinephrine.

The shift toward immunotherapy reflects a broader change in how peanut allergy is managed clinically. Patients and caregivers increasingly expect treatment options that reduce sensitivity over time rather than only treating acute episodes. Companies investing in improved delivery formats, including epicutaneous patches and sublingual formulations, are targeting better compliance and reduced risk of adverse events during treatment, particularly in pediatric populations where long-term adherence is a critical concern.

Regional Outlook Across Key Markets

• The USA leads growth at 12.5%, supported by high peanut allergy prevalence, established immunotherapy prescribing infrastructure, and growing insurance coverage for desensitization treatments.
• China follows at 12.0%, with growth shaped by rising allergy diagnosis rates, expanding hospital-based treatment programs, and growing awareness of allergy management options.
• Japan at 11.4% reflects strong clinical adoption of immunotherapy protocols, established allergy specialist networks, and supportive regulatory frameworks for desensitization products.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Peanut Allergy Treatment in the United States

The USA peanut allergy treatment market is projected to grow at a CAGR of 12.5% through 2036. Growth is supported by high peanut allergy prevalence, strong immunotherapy prescribing infrastructure, and expanding insurance coverage for desensitization therapies.

• High prevalence supports sustained demand for both emergency and desensitization products.
• Insurance coverage for immunotherapy is expanding across major payor groups.
• Clinical specialist networks enable structured desensitization protocol delivery.

Peanut Allergy Treatment Demand Trends in China

The China peanut allergy treatment market is projected to grow at a CAGR of 12.0% through 2036. Growth reflects rising allergy diagnosis rates, expanding hospital-based treatment capacity, and growing public awareness of allergy management beyond emergency care.

• Rising diagnosis rates expand the treatable patient population.
• Hospital-based treatment programs support immunotherapy adoption.
• Growing allergy awareness drives demand beyond emergency epinephrine.

Japan Peanut Allergy Treatment Market Growth Outlook

The Japan peanut allergy treatment market is projected to grow at a CAGR of 11.4% through 2036. Demand is supported by established allergy specialist networks, strong clinical adoption of immunotherapy protocols, and supportive regulatory pathways.

• Allergy specialist networks provide structured treatment delivery.
• Regulatory support accelerates immunotherapy product availability.
• High clinical standards drive adoption of evidence-based protocols.

Germany Peanut Allergy Treatment Market Demand Analysis

The Germany peanut allergy treatment market is projected to grow at a CAGR of 10.9% through 2036. Demand is supported by well-developed allergy care infrastructure, strong clinical research base, and established reimbursement frameworks.

• Allergy care infrastructure supports structured treatment delivery.
• Clinical research base strengthens evidence for immunotherapy adoption.
• Reimbursement frameworks support patient access to desensitization therapies.

Peanut Allergy Treatment Market Opportunity Outlook in India

The India peanut allergy treatment market is projected to grow at a CAGR of 10.3% through 2036. Growth reflects rising allergy awareness, expanding urban healthcare infrastructure, and growing demand for allergy management beyond emergency response.

• Rising allergy awareness drives diagnostic and treatment demand.
• Urban healthcare expansion supports specialist allergy care access.
• Growing middle-class health expenditure supports treatment adoption.

Competitive Benchmarking and Company Positioning

Peanut Allergy Treatment Market Analysis By Company

• Aimmune Therapeutics (Nestle Health Science), DBV Technologies, Sanofi, and ALK-Abello hold leading positions through approved desensitization products, active clinical pipelines, and established relationships with allergy specialist networks.
• Prota Therapeutics, Camallergy, and Aravax are advancing novel immunotherapy approaches across oral, epicutaneous, and modified allergen formats, targeting improved safety profiles and compliance in pediatric populations.
• Competition is shaped by the transition from emergency epinephrine dominance toward multi-format immunotherapy portfolios. Companies that secure broad reimbursement coverage and demonstrate improved safety in desensitization protocols are positioned to capture the fastest-growing segments.
• Strategic priorities include expanding immunotherapy delivery format options, building real-world evidence for desensitization efficacy, securing payor coverage across key markets, and investing in pediatric-focused clinical programs. Companies with both emergency and desensitization product portfolios can capture full patient lifecycle value.

Key Companies in the Peanut Allergy Treatment Market

• Aimmune Therapeutics, Inc., DBV Technologies S.A., Sanofi S.A., ALK-Abello A/S are among the leading players in the peanut allergy treatment market globally, supported by strong brand visibility, broad product portfolios, and established market positions.
• Prota Therapeutics Pty Ltd, Camallergy Ltd, Aravax Pty Ltd hold established positions across specific segments and channels, supported by targeted products and growing market presence.
• Genentech, Inc., Regeneron Pharmaceuticals, Inc., Stallergenes Greer Ltd. compete through focused product offerings and niche strength in specific applications and regional markets.

Recent Industry Developments

• Aimmune Therapeutics (Nestle Health Science) / Commercial Expansion / Market Access (2025)
  • Aimmune Therapeutics continued commercial expansion of its approved oral immunotherapy product for peanut allergy desensitization, with focus on broadening payor coverage and physician adoption across the United States and European markets.
• DBV Technologies S.A. / Clinical Development / Regulatory Submission (2025)
  • DBV Technologies advanced its epicutaneous immunotherapy patch program for peanut allergy treatment, progressing through clinical trials designed to demonstrate improved compliance and safety in pediatric patients.
• Regeneron Pharmaceuticals, Inc. / Clinical Trial / Biologic Therapy (2025)
  • Regeneron advanced clinical development of biologic therapies with potential application in food allergy management, exploring combination approaches that target underlying immune mechanisms alongside desensitization protocols.

Leading Companies Shaping the Peanut Allergy Treatment Market

• Aimmune Therapeutics, Inc.
• DBV Technologies S.A.
• Sanofi S.A.
• ALK-Abello A/S
• Prota Therapeutics Pty Ltd
• Camallergy Ltd
• Aravax Pty Ltd
• Genentech, Inc.
• Regeneron Pharmaceuticals, Inc.
• Stallergenes Greer Ltd.

Sources and Research References

• U.S. Food and Drug Administration (FDA). Peanut allergy treatment regulatory approvals and clinical guidelines.
• European Medicines Agency (EMA). Immunotherapy product assessments and regulatory frameworks.
• Aimmune Therapeutics. Product portfolio, commercial updates, and clinical data.
• DBV Technologies. Epicutaneous immunotherapy clinical trial data and regulatory submissions.
• World Allergy Organization. Global peanut allergy prevalence and treatment guidelines.
• Primary interviews with pharmaceutical companies, allergy specialists, immunologists, hospital pharmacists, and patient advocacy groups.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Peanut Allergy Treatment market?
• How fast is the Peanut Allergy Treatment market expected to grow between 2026 and 2036?
• Which drug class is likely to lead the market by 2026?
• Which application segment is expected to account for the highest demand by 2026?
• What factors are driving demand for peanut allergy treatments globally?
• How is the shift toward immunotherapy influencing the market?
• Why is the United States the fastest-growing market?
• How are regulatory approvals supporting treatment adoption?
• Which countries are projected to show the fastest growth through 2036?
• Who are the key companies active in the Peanut Allergy Treatment market?
• How does Fact.MR estimate and validate the market forecast?

Peanut Allergy Treatment Market Definition

The peanut allergy treatment market covers pharmaceutical and immunotherapy-based interventions for managing peanut allergy, including epinephrine auto-injectors, antihistamines, and oral, epicutaneous, and sublingual immunotherapy products used across emergency management, desensitization therapy, and preventive care applications.

Peanut Allergy Treatment Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across drug class, route of administration, distribution channel, application, and region.
• It includes regional demand analysis based on peanut allergy prevalence, treatment adoption rates, immunotherapy access, and reimbursement frameworks.
• The report includes pricing and cost analysis across epinephrine products, immunotherapy protocols, and related healthcare services.
• It covers clinical pipeline developments, regulatory pathways, market drivers and constraints, and the competitive landscape of leading pharmaceutical and biotech companies.

Peanut Allergy Treatment Market Exclusions

• The scope excludes general allergy treatments not specific to peanut allergy, including broad-spectrum antihistamines used for non-food allergies.
• It excludes diagnostic testing products and allergy screening services not bundled with treatment protocols.
• The report excludes nutritional products, peanut-free food alternatives, and allergen avoidance products without pharmaceutical classification.
• It also excludes experimental gene therapy approaches and academic research programs without commercial product development pathways.

Peanut Allergy Treatment Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 90+ secondary sources and benchmarks 30+ company product portfolios and clinical pipelines.
• Market sizing covers 30+ countries through a demand-side model, supported by top-down validation.
• Key inputs include peanut allergy prevalence, treatment adoption rates, immunotherapy access, reimbursement coverage, and clinical trial outcomes.
• The model cross-checks demand with prescription data, pricing trends, distribution patterns, and regulatory timelines.
• Primary validation includes 20+ interviews across pharmaceutical companies, allergy specialists, hospital pharmacies, and patient advocacy organizations.
• Final estimates go through clinical adoption rate validation, reimbursement impact analysis, and sensitivity testing.